
Understanding off-target ADC lung toxicity: why human-relevant models matter
In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.
DateCategory
Watch Time
13 minutes
In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.
As ADC formats become more complex, the need for earlier, more mechanistic safety insight becomes more important. This session looks at why interstitial lung disease remains such a difficult risk to predict, why alveolar macrophages are central to the story, and how human-relevant in vitro models can help teams make safer, more informed decisions earlier in development.
In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.
As ADC formats become more complex, the need for earlier, more mechanistic safety insight becomes more important. This session looks at why interstitial lung disease remains such a difficult risk to predict, why alveolar macrophages are central to the story, and how human-relevant in vitro models can help teams make safer, more informed decisions earlier in development.